Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer.

The early detection of colorectal cancer originating from any part of the colorectum is desirable because this cancer can be cured surgically if diagnosed early. We searched for marker genes for a fecal RNA-based colorectal cancer screening method by comparison of genome-wide expression profiles among cancerous and non-cancerous tissues, and healthy volunteer- and cancer patient-derived colonocytes from the feces, and the peripheral blood. Of 14,564 genes, only 3 (PAP, REG1A, and DPEP1) were selectable as final candidates which were expressed frequently at any stage of this cancer and were suppressed in non-cancerous tissues and also in the peripheral blood and colonocytes of healthy volunteers. Next, we directly compared fecal RNA-expression profiles between colorectal cancer patients and healthy volunteers, and found that most of the genes (92%) expressed in the colonocytes of the cancer patients were not expressed in those of the healthy volunteers. Six genes (SEPP1, RPL27A, ATP1B1, EEF1A1, SFN, and RPS11) selected randomly from 85 cancer patient-derived colonocyte-specific genes were evaluated. In total, reverse transcription-polymerase chain reaction or focused microarray of all those 9 genes detected 18 (78%) of 23 curable colorectal cancers (Dukes stages A-C), 9 or 10 (64% or 71%) of 14 early cancers with no lymph node metastasis (Dukes stage A or B) and 4 (80%) of 5 right-sided cancers. Our extensive gene list provides other markers for fecal RNA-based colorectal cancer screening.

[1]  K. Kinzler,et al.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. , 1992, Science.

[2]  D. Tarin,et al.  Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells , 1994, BMJ.

[3]  C. Wagener,et al.  Detection of K‐ras mutations in stools of patients with colorectal cancer by mutant‐enriched PCR , 1996, International journal of cancer.

[4]  N. Yamamoto,et al.  Microarray fabrication with covalent attachment of DNA using Bubble Jet technology , 2000, Nature Biotechnology.

[5]  D. Tarin,et al.  Significance of CD44 gene products for cancer diagnosis and disease evaluation , 1992, The Lancet.

[6]  K. Kinzler,et al.  Detection of proximal colorectal cancers through analysis of faecal DNA , 2002, The Lancet.

[7]  T. Church,et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer. , 2000, The New England journal of medicine.

[8]  K. Mafune,et al.  Highly specific marker genes for detecting minimal gastric cancer cells in cytology negative peritoneal washings. , 2004, Biochemical and biophysical research communications.

[9]  S. Goodman,et al.  Detecting colorectal cancer in stool with the use of multiple genetic targets. , 2001, Journal of the National Cancer Institute.

[10]  Masaaki Ito,et al.  A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. , 2005, Gastroenterology.

[11]  P. Glasziou,et al.  A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. , 1998, BMJ.

[12]  S. Thibodeau,et al.  Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. , 2000, Gastroenterology.

[13]  J. Olsen,et al.  Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.

[14]  H. Ohta,et al.  Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). , 1995, Oncogene.

[15]  W. Bodmer,et al.  Detection of cKi-ras mutations in faecal samples from sporadic colorectal cancer patients , 2006 .

[16]  W. Bodmer,et al.  Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. , 1995, Gut.

[17]  D. Amadori,et al.  Multiple detection of genetic alterations in tumors and stool. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  G. Curigliano,et al.  Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces , 1996, Diseases of the colon and rectum.

[19]  T. Kanematsu,et al.  Mutations of the p53 gene in the stool of patients with resectable colorectal cancer , 1996, Cancer.

[20]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[21]  Y. Kodera,et al.  Detection of Minimal Gastric Cancer Cells in Peritoneal Washings by Focused Microarray Analysis with Multiple Markers: Clinical Implications , 2007, Annals of Surgical Oncology.

[22]  K. Kinzler,et al.  Detection of APC mutations in fecal DNA from patients with colorectal tumors. , 2002, The New England journal of medicine.

[23]  K. Sugihara,et al.  Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. , 1998, Gastroenterology.

[24]  R. Deuter,et al.  Detection of APC mutations in stool DNA of patients with colorectal cancer by HD‐PCR , 1998, Human mutation.

[25]  L M Schuman,et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.

[26]  S. Woolf,et al.  Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. , 2003, Gastroenterology.

[27]  D. Ahlquist,et al.  DNA integrity as a potential marker for stool-based detection of colorectal cancer. , 2003, Clinical chemistry.